Clazosentan
- Product Name
- Clazosentan
- CAS No.
- 180384-56-9
- Chemical Name
- Clazosentan
- Synonyms
- VML 588;AXV-034343;Clazosentan;Clazosentan Sodium;Clazosentan Soudium;Octahydroaminoacridine succinate;Clazosentan (Ro-61-1790, ACT-108475);N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2-[2-(2H-TETRAZOL-5-YL)-4-PYRIDINYL]-4-PYRIMIDINYL]-5-METHYL-2-PYRIDINESULFONAMIDE;N-(2-(2-(2H-tetrazol-5-yl)pyridin-4-yl)-6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide;N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-methyl-pyridine-2-sulfonamide
- CBNumber
- CB01856019
- Molecular Formula
- C25H23N9O6S
- Formula Weight
- 577.57
- MOL File
- 180384-56-9.mol
Clazosentan Property
- Melting point:
- 239-241°
- Boiling point:
- 754.5±70.0 °C(Predicted)
- Density
- 1.485±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO : 83.33 mg/mL (144.28 mM; Need ultrasonic)
- form
- Solid
- pka
- 2.97±0.10(Predicted)
- color
- Off-white to light yellow
- InChIKey
- LFWCJABOXHSRGC-UHFFFAOYSA-N
- SMILES
- C1(S(NC2C(OC3=CC=CC=C3OC)=C(OCCO)N=C(C3C=CN=C(C4=NNN=N4)C=3)N=2)(=O)=O)=NC=C(C)C=C1
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- C565400
- Product name
- Clazosentan
- Packaging
- 150mg
- Price
- $6545
- Updated
- 2021/12/16
Clazosentan Chemical Properties,Usage,Production
Description
Clazosentan (trade name Pivlaz) is a small molecule endothelin (ET) A receptor selective antagonist developed by Idorsia Pharmaceuticals. By inhibiting the ET A receptor, clazosentan sodium can reduce ET-related cerebral vasospasm that may occur after cerebral aneurysmal subarachnoid hemorrhage.
Uses
Clazosentan, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain injury.
Synthesis
Under alkaline conditions, o-hydroxyanisole (11.1) was alkylated with diethyl bromomalonate, followed by cyclization of the diester 11.2 and the amidine 11.3 to give the pyrimidine 11.4. Amidation of the pyridine ring was performed under modified Minisci conditions, but no yields were reported for the conversion of pyridine 11.4 to 2-carboxyamide pyridine 11.5. Addition of dihydroxypyrimidine 11.5 to phosphorus oxychloride under alkaline conditions resulted in conversion of the hydroxyl group to the corresponding chloride, with simultaneous dehydration of the amide to give the nitrile 11.6. Substitution with commercially available sulfonamide 11.7 under mild conditions allowed the introduction of a single pyridinesulfonamide 11.8, followed by nucleophilic addition of hydrazine to the nitrile to give the iminohydrazine 11.9. Treatment with sodium nitrite under weakly acidic conditions promoted tetrazole formation, followed by substitution of the remaining aryl chloride with ethylene glycol in the presence of sodium hydroxide. The remaining aryl chloride underwent substitution with ethylene glycol. Finally, exposure of clazotan to heated sodium methoxide/methanol followed by careful cooling and filtration afforded the disodium salt of clazotan sodium (11) in 41% yield from chloropyrimidine 11.10.
in vivo
Clazosentan (10 μM, 0.05?mL/kg, intracisternal injection) inhibits the contractile responses to ET-1 in rats[2]. Clazosentan (10 mg/kg, s.c.) inhibits IL-33-induced hypernociception in mice[4].
| Animal Model: | Rats[2] |
| Dosage: | 10 μM, 0.05?mL/kg |
| Administration: | Intracisternal injection |
| Result: | Inhibited the contractile responses to ET-1, without preventing SAH-induced upregulation of ET receptors in cerebral arteries. |
Clazosentan Preparation Products And Raw materials
Raw materials
Preparation Products
Clazosentan Suppliers
- Tel
- 13012344321
- 3995296515@qq.com
- Country
- China
- ProdList
- 8439
- Advantage
- 58
- Tel
- 023-68625073 15723208759
- lidaijun@midecopharm.com
- Country
- China
- ProdList
- 68
- Advantage
- 58
- Tel
- 18210857532; 18210857532
- Fax
- 86-10-82849933
- jkinfo@jkchemical.com
- Country
- China
- ProdList
- 96815
- Advantage
- 76
- Tel
- 021-33632979
- Fax
- 021-34692979
- info@tsbiochem.com
- Country
- China
- ProdList
- 8065
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- Fax
- 021-65675885
- info@efebio.com
- Country
- China
- ProdList
- 9803
- Advantage
- 58
- Tel
- +86-400-002-6226 +86-13028896684;
- sales@rrkchem.com
- Country
- China
- ProdList
- 57422
- Advantage
- 58
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- +86-27-50766799 +8618062016861
- contact@labnetwork.com
- Country
- China
- ProdList
- 19987
- Advantage
- 58
- Tel
- 020-82000279 18988941452
- Fax
- QQ：3283937693
- YN_research@163.com
- Country
- China
- ProdList
- 3011
- Advantage
- 58
- Tel
- 021-58432009 400-005-6266
- Fax
- 021-58436166
- marketing@energy-chemical.com
- Country
- China
- ProdList
- 44918
- Advantage
- 58
View Lastest Price from Clazosentan manufacturers
- Product
- Clazosentan 180384-56-9
- Price
- US $5.00-0.50/KG
- Min. Order
- 1KG
- Purity
- 99% hplc
- Supply Ability
- 500TONS
- Release date
- 2025-06-05